Table 6.

Percentage of selected ACTs by quantity of stated API for artemisinin component and partner drug

(a) All ACTs analyzed (N = 1,281)
Partner drug
Artemisinin component	%API	55–65	65–75	75–85	85–115	115–125	> 125	Total
	55–65	< 0.1	0	0.1	< 0.1	< 0.1	0	0.2
	65–75	0	0.1	0	< 0.1	0	0	0.2
	75–85	0	0	< 0.1	1.7	0.1	0	1.9
	85–115	0	0	3.3	87.9	2.7	0.6	94.4
	115–125	0	< 0.1	0	1.4	1.5	0	2.9
	> 125	0	0	0	0.2	0.1	0	0.3
	Total	< 0.1	0.2	3.4	91.3	4.5	0.6	100
(b) Alu (N = 504)
Lumefantrine
Artemether drugs	%API	55–65	65–75	75–85	85–115	115–125	> 125	Total
	55–65	0	0	0	0	0	0	0.0
	65–75	0	0	0	0	0	0	0.0
	75–85	0	0	0	< 0.1	0	0	< 0.1
	85–115	0	0	0.2	96.9	1.0	0	98.0
	115–125	0	0	0	1.4	0	0	1.4
	> 125	0	0	0	0.6	0	0	0.6
	Total	0.0	0.0	0.2	98.9	1.0	0.0	100
(c) Artemisinin–piperaquine (N = 173)
Piperaquine
Artemisinin	%API	55–65	65–75	75–85	85–115	115–125	> 125	Total
	55–65	0	0	0	0	0	0	0.0
	65–75	0	0	0	0	0	0	0.0
	75–85	0	0	0	3.6	0	0	3.6
	85–115	0	0	0.9	88.5	2.7	4.3	96.4
	115–125	0	0	0	0	0	0	0.0
	> 125	0	0	0	0	0	0	0.0
	Total	0.0	0.0	0.9	92.1	2.7	4.3	100
(d) Artesunate–mefloquine (N = 310)
Mefloquine
Artesunate	%API	55–65	65–75	75–85	85–115	115–125	> 125	Total
	55–65	<0.1	0	0.6	<0.1	0.2	0	1.0
	65–75	0	0.6	0	0.4	0	0	1.0
	75–85	0	0	0	0.9	0.6	0	1.5
	85–115	0	0	0.3	80.8	3.7	< 0.1	84.9
	115–125	0	0.2	0	3.4	7.5	0	11.2
	> 125	0	0	0	0	0.6	0	0.6
	Total	< 0.1	0.8	0.9	85.5	12.6	< 0.1	100
(e) Dihydroartemisinin–piperaquine (N = 294)
Piperaquine
Dihydroartemisinin	%API	55–65	65–75	75–85	85–115	115–125	> 125	Total
	55–65	0	0	0	0	0	0	0.0
	65–75	0	0	0	0	0	0	0.0
	75–85	0	0	0.2	4.1	0	0	4.2
	85–115	0	0	11.6	78.9	4.7	0.1	95.3
	115–125	0	0	0	0.4	0	0	0.4
	> 125	0	0	0	0	0	0	0.0
	Total	0.0	0.0	11.8	83.4	4.7	0.1	100

ACT = artemisinin-based combination therapy; Alu = artemether–lumefantrine; API = active pharmaceutical ingredient.

The percentage of samples containing acceptable quantities of API for both the artemisinin component and partner drug is shown in bold.